Our News
Read about our latest news, events and updates
August 11, 2022
PsiOxus Therapeutics Appoints Howard Davis, Ph.D. as Chief Executive Officer
September 15, 2021
PsiOxus to Present Positive Biomarker Data at ESMO 2021 Demonstrating the Potential of Their Novel Tumor-Selective T-SIGn® vector, NG-350A, to Re-Engineer Advanced Cancers
April 14, 2021
PsiOxus and bluebird bio Present Novel Data Combining PsiOxus T-SIGn Platform with CAR-T Therapy to Clear Primary Tumors and Metastases
April 7, 2021
PsiOxus Therapeutics updates agreement with Bristol-Myers Squibb to advance their clinical stage immuno-oncology collaboration
March 5, 2020
PsiOxus Therapeutics Announces Clinical Trial with Third Cancer Gene Therapy Treatment and Appointment of New Chief Medical Officer.